Defining process design space for monoclonal antibody cell culture
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The concept of design space has been taking root as a foundation of in‐process control strategies for biopharmaceutical manufacturing processes. During mapping of the process design space, the multidimensional combination of operational variables is studied to quantify the impact on process performance in terms of productivity and product quality. An efficient methodology to map the design space for a monoclonal antibody cell culture process is described. A failure modes and effects analysis (FMEA) was used as the basis for the process characterization exercise. This was followed by an integrated study of the inoculum stage of the process which includes progressive shake flask and seed bioreactor steps. The operating conditions for the seed bioreactor were studied in an integrated fashion with the production bioreactor using a two stage design of experiments (DOE) methodology to enable optimization of operating conditions. A two level Resolution IV design was followed by a central composite design (CCD). These experiments enabled identification of the edge of failure and classification of the operational parameters as non‐key, key or critical. In addition, the models generated from the data provide further insight into balancing productivity of the cell culture process with product quality considerations. Finally, process and product‐related impurity clearance was evaluated by studies linking the upstream process with downstream purification. Production bioreactor parameters that directly influence antibody charge variants and glycosylation in CHO systems were identified. Biotechnol. Bioeng. 2010;106: 894–905. © 2010 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Current and future issues in the manufacturing and development of monoclonal antibodies
Kozlowski, S., & Swann, P. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.05.002 · Cited by 170 · cited 1×
“…anticipated to be implemented throughout the lifecycle of a product— starting with process design and definition, moving on to process characterization and validation and finally to monitoring and control of the commercial manufacturing process (Kozlowski and Swann, 2006; Rathore and Winkle, 2009).”
Background
Cited by
Trends in Upstream and Downstream Process Development for Antibody Manufacturing
Gronemeyer, P., Ditz, R., & Strube, J. (2014) · Bioengineering · doi:10.3390/bioengineering1040188 · Cited by 329
Scale‐Down Model Development in ambr systems: An Industrial Perspective
Sandner, V., Pybus, L. P., McCreath, G., & Glassey, J. (2019) · Biotechnology Journal · doi:10.1002/biot.201700766 · Cited by 63
Perfusion culture of Chinese Hamster Ovary cells for bioprocessing applications
MacDonald, M. A., Nöbel, M., Roche Recinos, D., Martínez, V. S., Schulz, B. L., Howard, C. B., Baker, K., Shave, E., Lee, Y. Y., Marcellin, E., et al. (2022) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2021.1998821 · Cited by 55
Nagashima, H., Watari, A., Shinoda, Y., Okamoto, H., & Takuma, S. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23744 · Cited by 52
Konakovsky, V., Clemens, C., Müller, M., Bechmann, J., Berger, M., Schlatter, S., & Herwig, C. (2016) · Bioengineering · doi:10.3390/bioengineering3010005 · Cited by 44
“This naturally has an impact on subsequent unit operations [106], which, for example, include time-intensive separation, washing and purification steps [92,107] (Figure 11).”
Background
Metadata
- Authors
- Abu‐Absi, S. F., Yang, L., Thompson, P., Jiang, C., Kandula, S., Schilling, B., & Shukla, A. A.
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2010-06-29
- Volume
- 106
- Issue
- 6
- Pages
- 894-905
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W2155020140
- Cited by
- 107
- References
- 1
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Defining process design space for monoclonal antibody cell culture. https://app.cochat.ai/papers/10.1002/bit.22764
- The paper
- Abu‐Absi, S. F., Yang, L., Thompson, P., Jiang, C., Kandula, S., Schilling, B., & Shukla, A. A. (2010). Defining process design space for monoclonal antibody cell culture. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.22764
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.